Navigation Links
Unigene Reports Third Quarter 2011 Financial Results
Date:11/9/2011

uding any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com / amielach@tiberend.com

Tables to followUNIGENE LABORATORIES, INC.CONDENSED BALANCE SHEETSSeptember 30, 2011December 31, 2010ASSETS

(Unaudited)Current assets:Cash and cash equivalents

$5,193,019$12,200,800Accounts receivable

1,570,7051,553,091Accounts receivable – Tarsa

463,204186,263Inventory, net

1,707,1621,417,934Prepaid expenses and other current assets

220,172699,950Due from former China joint venture partner

600,000--Total current assets

9,754,26216,058,038Noncurrent inventory

1,985,5412,881,980Property, plant and equipment, net

3,070,9863,190,117Patents and other intangibles, net

1,999,4322,670,044Investment in former China joint venture

--3,175,925Investment in Tarsa

----Deferred financing costs, net

119,834181,457Other assets

569,492313,382Total assets

$17,499,547$28,470,943LIABILITIES AND STOCKHOLDERS' DEFICITCurrent liabilities:Accounts payable

$ 1,235,206$974,998Accrued expenses

2,122,4762,834,345Current portion - deferred licensing fees

2,738,9292,290,916Current portion – deferred gain on sale/leaseback

116,76
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
2. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. GenVec Reports Third Quarter 2011 Financial Results
5. Chindex International, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. Allied Healthcare Products Reports First Quarter Loss on Sales Decline
7. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
8. Stereotaxis Reports Third Quarter Financial Results
9. Isis Reports Financial Results and Highlights for Third Quarter 2011
10. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
11. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... will host a webcast conference call to report its ... on the company,s business and outlook on Thursday, August ... of the market. The call can ... 935-8152 (international) five minutes prior to the start of ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
(Date:7/24/2014)... Deutschland, und MARSEILLE , ... , Weltweite Exklusivlizenz der ... QIAGEN die Entwicklung von Tests auf SF3B1-Mutationen, ... Neuer Test weist Mutationen des ... (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/24/2014)... Tenn. Researchers at Le Bonheur Children,s Hospital and ... of a clinical trial of a new drug shown ... of healthy adult volunteers intranasally infected with respiratory syncytial ... lower respiratory tract infections in young children in the ... from the labs of Infectious Disease Specialist John DeVincenzo, ...
(Date:7/24/2014)... In signing the Workforce Innovation ... the Atlanta BeltLine Workforce Partnership in Healthcare as ... country ( http://www.whitehouse.gov/ready-to-work ). The Administration called ... U.S. economic strategy and profiled successful local efforts ... President Obama highlights the power of partnerships in ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... PROVIDENCE, R.I. Lynn E. Taylor, M.D., director ... states in the July, 2014 Rhode Island ... C" that eliminating hepatitis c virus infection (hep ... benefits, enhance capacity to address other health challenges, ... HCV in the United States, Taylor says, include ...
Breaking Medicine News(10 mins):Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... POTOMAC FALLS, Va., Nov. 3 "When my father ... read every book,pamphlet, and newspaper article I could get ... book, "A Conversation About Alzheimer,s" (published by,AuthorHouse -- ... think about. I told myself that once I knew ...
... more common for adolescents illegally at the wheel, study finds, ... the thought of teenagers driving before they,ve gotten their license ... are also more likely to drive while drinking or on ... get behind the wheel. , Reporting in the November issue ...
... JOHNSON,S(R) Partners With MARCH OF DIMES(R) To Build ... The United States, SKILLMAN, N.J., Nov. 3 ... of "Prematurity Awareness Month" that partners,with the March ... growing problem of,premature birth and raise funds to ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (Nasdaq: CHBT ) ... the research, development, manufacture, marketing and,distribution of probiotics ... call at 9:00 a.m. EST on Tuesday, November ... the second quarter ended,September 30, 2008, of its ...
... Nov. 3 Hooper Holmes,(Amex: HH ) today ... before market on Friday, November 7, 2008. The Company,will ... at 11:00am Eastern,Time., Conference Call, To participate ... code: Hooper Holmes. A live web cast will be ...
... Inc. (Nasdaq: MBRK ), a pharmaceutical ... products, today,announced that it has retained national ... will serve as MiddleBrook,s strategic and tactical ... reimbursement, contract,administration, national account management and government ...
Cached Medicine News:Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Many Unlicensed Teen Drivers Put Safety Last 2Health News:Many Unlicensed Teen Drivers Put Safety Last 3Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 2Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 3Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 2Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 3Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
... Liquichek Hematology-16 Control ... use on most hematology ... to 16 parameters and ... differentials. This trilevel control ...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... Amplichek CT/GC Controls are liquid ... precision of test procedures that ... gonorrhoeae. Since they are specimen ... with either urine or endocervical/urethral ...
Medicine Products: